Alvotech (ALVO) Projected to Post Earnings on Tuesday

Alvotech (NASDAQ:ALVO - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 20th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $95.02 million for the quarter.

Alvotech (NASDAQ:ALVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.52. On average, analysts expect Alvotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alvotech Trading Down 0.4%

NASDAQ:ALVO traded down $0.04 on Thursday, reaching $10.46. 176,535 shares of the stock traded hands, compared to its average volume of 137,218. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of -5.65 and a beta of -0.02. Alvotech has a 12 month low of $7.35 and a 12 month high of $14.65. The company's fifty day simple moving average is $9.41 and its 200 day simple moving average is $11.37.

Analyst Upgrades and Downgrades

Separately, UBS Group started coverage on shares of Alvotech in a research note on Friday, February 14th. They set a "buy" rating and a $18.00 price objective for the company.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.